Gilead Sciences Inc. has entered a definitive agreement under which it will acquire CymaBay Therapeutics Inc. for $32.50 per share in cash or a total equity value of $4.3 billion.   The addition of CymaBay’s investigational lead product candidate, seladelpar for the treatment of primary biliary cholangitis (PBC) including pruritus, complements Gilead’s existing liver portfolio and aligns with its commitment to bringing transformational medicines to patients. Addressing Unmet Needs for Peop...